Efficacy Evaluation of the Mahuang-Fuzi-Xixin Decoction in Combination with Shenmai Injection for Bradyarrhythmia Treatment: A Systematic Review and Meta-Analysis

Table 1

Basic characteristics of included studies.

Study	Sample size	Age (years)	Sex M/F	24 h-hour mean heart rate	24 h-hour minimal heart rate	TCMSS	Intervention measures		Treatment duration	Outcomes	Adverse events
	I/C	I/C					I	C
Yao Yunhan 2019 [11]	80/80	I: 45.63 ± 4.57	I: 45/35	I: 51.55 ± 2.69	I: 41.33 ± 3.15	I: 16.33 ± 2.15	SMI + MFX	SMI	4 w	①②③④	Not reported
		C: 45.72 ± 4.26	C: 42/38	C: 51.62 ± 2.52	C: 41.37 ± 3.28	C: 16.23 ± 2.35
Liang Yuting 2018 [16]	25/25	I: 60.4	I: 13/12	I: 43.2 ± 4.3	I: 36.2 ± 5.0	—	SMI + MFX	SMI	—	①②③	Occurrence
		C: 62	C: 16/9	C: 42.5 ± 4.6	C: 37.4 ± 5.2
Wu Hao 2017 [19]	38/38	I: 64 ± 6	I: 19/19	—	—	—	SMI + MFX	SMI	4 w	③	Occurrence
		C: 62 ± 6	C: 20/18
Li Xuemin 2017 [22]	45/45	I: 42.03 ± 4.27	I: 25/20	I: 51.63 ± 3.18	I: 41.23 ± 3.57	I: 16.53 ± 2.13	SMI + MFX	SMI	—	①②③④	Not reported
		C: 41.27 ± 4.59	C: 24/21	C: 51.77 ± 3.24	C: 41.42 ± 4.06	C: 15.93 ± 3.14
Li Dali 2016 [21]	32/32	I: 60.3 ± 3.1	I: 18/14	I: 43.2 ± 4.6<	I: 36.5 ± 5.0	-	SMI + MFX	SMI	30 d	①②③	Occurrence
		C: 61.2 ± 3.2	C: 17/15	C: 42.9 ± 4.3	C: 37.1 ± 5.1
Liu Yaowen 2015 [17]	40/40	I/C: 42.4 ± 3.1	I/C: 43/37	—	—	—	SMI + MFX	SMI	4 w	③	Not reported
Chang Xinhai 2015 [20]	34/34	I/C: 42.4 ± 3.1	I/C: 38/30	—	—	—	SMI + MFX	SMI	4 w	③	Not reported
Qin Guige 2013 [18]	46/46	I/C: 48 ± 11.29	I/C: 51/41	—	—	—	SMI + MFX	SMI	4 w	③	Not reported

I: intervention group; C: control group; M: male; F: female; w: weeks; d: days; ① 24-hour mean heart rate; ② 24-hour minimal heart rate; ③ Efficacy; ④ TCMSS.